Details for New Drug Application (NDA): 022192
✉ Email this page to a colleague
NDA 022192 describes FANAPT, which is a drug marketed by Vanda Pharms Inc and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FANAPT profile page.
The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iloperidone profile page.
The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iloperidone profile page.
Summary for 022192
| Tradename: | FANAPT |
| Applicant: | Vanda Pharms Inc |
| Ingredient: | iloperidone |
| Patents: | 9 |
Suppliers and Packaging for NDA: 022192
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FANAPT | iloperidone | TABLET;ORAL | 022192 | NDA | Vanda Pharmaceuticals Inc. | 43068-101 | 43068-101-02 | 60 TABLET in 1 BOTTLE (43068-101-02) |
| FANAPT | iloperidone | TABLET;ORAL | 022192 | NDA | Vanda Pharmaceuticals Inc. | 43068-102 | 43068-102-02 | 60 TABLET in 1 BOTTLE (43068-102-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | May 6, 2009 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Apr 2, 2027 | ||||||||
| Regulatory Exclusivity Use: | INDICATED FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Nov 2, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6 | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Aug 31, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ||||||||
Expired US Patents for NDA 022192
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-007 | May 6, 2009 | ⤷ Subscribe | ⤷ Subscribe |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | ⤷ Subscribe | ⤷ Subscribe |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-004 | May 6, 2009 | ⤷ Subscribe | ⤷ Subscribe |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-006 | May 6, 2009 | ⤷ Subscribe | ⤷ Subscribe |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | ⤷ Subscribe | ⤷ Subscribe |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-005 | May 6, 2009 | ⤷ Subscribe | ⤷ Subscribe |
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
